BCR-ABL Monitoring

Biocerna performs tests for both the major (p210) and minor (p190) translocations of the BCR-ABL genes. These tests are typically utilized to monitor patient's response to chemotherapy.  

Biocerna provides all BCR-ABL results in a test report that provides a longitudinal view of all tests we have performed for your patient. Results are reported using both log and fold changes from their last test result.

Biocerna reports all results for the Major Translocation using the International Scale. 




Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit allows for highly sensitive detection of p210 translocations and chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based In Vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.


We utilize the QuantideX® qPCR BCR-ABL minor Kit to enable sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens.